One of the essential pathological signatures of Alzheimer’s disease is deposition in the brain of an abnormal protein, called Aβ-amyloid (Aβ). About three decades before the onset of dementia symptoms, the deposition starts silently, without any sign of cognitive abnormalities. It is estimated that about 20-40 % of the general elderly population have a significant... Read more
Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more
Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more
Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more
Enzo Life Sciences is proud to announce the introduction of three new clinically relevant antibodies for immunohistochemistry detection. When combined with Enzo’s enhanced detection system, our IHC solutions are among the most robust and cost-effective on the market. This furthers Enzo’s capabilities in the rapidly growing segment of Anatomical Pathology, and allows us to enable... Read more
FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, controlled trial intended... Read more
FRANKLIN LAKES, N.J., Jan. 17, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2018, at 1 p.m. (ET). The webcast can be accessed from the BD corporate website at http://www.bd.com/investors/ and... Read more
Download PDF Read more
FRANKLIN LAKES, N.J., and WAGENINGEN, The Netherlands, Jan. 15, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System. It... Read more
02. February 2018 – 07. February 2018 Visit Greiner Bio-One at Booth 629 at the SLAS in San Diego! SLAS2018 is the annual flagship International Conference and Exhibition from SLAS. Through a unique combination of education, access to innovative technologies and intelligent peer networking, SLAS2018 delivers unmatched value for professionals and students looking to discover... Read more